Biotech focuses on infusing biological processes with technology to improve human, animal, and environmental health. Biotech & Pharma businesses utilize technology to work toward disease prevention, treatment and cure. These businesses also work in Agtech and fuel development. Register today to discover how Forge can help you buy and sell private shares.
Register to add companies to your watchlist and get access to bids/asks activity, last matched price and trade eligibility details.
Register| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4 |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
| Elektrofi | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $284.44M | Series C | 8/8/2024 | $96.45M | $402.83M | $14.04 | Undisclosed Investors | |||||
| Escient Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $243.51M | Series C | 11/28/2022 | $120M | $256.49M | $0.75 | NEA, Abingworth, Forge Life Science Partners, Avego, PFM Health Sciences, The Eleven Fund, The Column Group, 5AM Ventures, Redmile Group, Cowen Healthcare Investments, Sanofi Ventures, Osage University Partners, Altitude Life Science Ventures | |||||
| Matchpoint Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $250M | Series B-1 | 10/7/2026 | $122.23M | $272.56M | $0.51 | Nextech Invest, Norwest, Invus, BB Biotech, T1D Fund, BOLD Longevity Growth, Access Biotechnology, Atlas Venture, Sanofi Ventures, Digitalis Ventures, Vertex Ventures HC, Alexandria Venture Investments, Binney Street Capital | |||||
| Mineralys | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $159.18M | Series B | 6/8/2022 | $118M | $267.43M | $0.86 | RA Capital Management, Andera Partners, RTW Investments, Rock Springs Capital, SR One Capital Management, Sectoral Asset Management, Ysis Capital, HealthCor Management, Boulder Ventures, Catalys Pacific, Samsara BioCapital, HBM Healthcare Investments, Adams Street Partners | |||||
| Prosetta Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $63.64M | Series D | 12/31/2015 | $31.1M | $378.68M | $4.50 | Takeda Ventures, Alger | |||||
| Scipher Medicine | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $238.76M | Series D | 2/24/2022 | $120.72M | $498.65M | $38.12 | Cowen Healthcare Investments, Neuberger Berman, Hitachi Ventures, Laurion Capital, Monashee Investment Management, Northpond Ventures, aMoon, Khosla Ventures, Optum Ventures, Echo Health Ventures, Alumni Ventures | |||||
| Scribe Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $120.71M | Series B | 3/31/2021 | $100M | $351.77M | $35.83 | Avoro Ventures, Avoro Capital Advisors, OrbiMed, Andreessen Horowitz, Perceptive Advisors, T. Rowe Price, Wellington Management, RA Capital Management, Menlo Venture | |||||
| ArriVent Biopharma | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $260M | Series B | 12/16/2022 | $110M | $375.08M | $1.05 | Undisclosed Investors | |||||
| ARS Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $76.55M | Series D | 8/31/2021 | $55M | $310.11M | $5.89 | SR One, RA Capital Management, Deerfield | |||||
| CinCor Pharma | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $192.86M | Series B | 10/12/2021 | $142.86M | $370.57M | $4.00 | General Atlantic, Perceptive Advisors, BVF Partners, venBio Partners, Adage Capital Management, Omega Funds, Rock Springs Capital, RTW Investments, Lilly Asia Ventures, Sixty Degree Capital, Sofinnova Investments, Sofinnova Partners, 5AM Ventures, CinRx | |||||
| Codiak BioSciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $168.37M | Series C | 11/29/2017 | $76.37M | $404.14M | $3.78 | ARCH Venture Partners, Flagship Pioneering, Fidelity Management and Research Company, the Alaska Permanent Fund, Alexandria Venture Investments | |||||
| Cullgen | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $116M | Series C | 5/8/2023 | $35M | $264.09M | $2.63 | AstraZeneca-CICCVentureCapitalPartnership, SincereCapital, VoyagersCapital, WuxiCapitalGroup, GHIGroup | |||||
| GenapSys | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $201.18M | Series D | 5/27/2021 | $70M | $463.55M | $7.84 | Farallon Capital Management, Soleus Capital | |||||
| HI-Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $22.2M | Series A | 10/20/2022 | $20M | $97.78M | $0.71 | Tom Brown, Jonas Schneider, Drew Houston, Arash Ferdowsi, Astera Institute | |||||
| IsoPlexis | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $161.52M | Series D | 1/7/2021 | $92.5M | $348.21M | $76.92 | Perceptive Advisors, Ally Bridge Group, BlackRock | |||||
| Jnana Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $414.4M | Series C-2 | 11/15/2022 | $47M | $292.93M | $0.89 | Bain Capital, RA Capital Management, Polaris Partners, Versant Ventures, Avalon Ventures, Pfizer Ventures | |||||
| Mariana Oncology | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $250M | Series B | 9/7/2023 | $175M | $311.65M | $1.06 | Deep Track Capital, Forbion, Atlas Ventures, Access Biotechnology, RA Capital Management, Nextech Invest, Surveyor Capital, Eli Lilly and Company | |||||
| NextPoint | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $196.84M | Series B | 7/30/2026 | $156.21M | $356.79M | $6.00 | Catalio Capital, MPM BioImpact, Leaps by Bayer, Sanofi Ventures, Invus, Sixty Degree Capital, Binney Street Capital, Gordon Freeman, Arkin Capital, WTT Investment, PagodaTree Partners | |||||
| Orphai Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $124.32M | Series 1-E | 8/1/2021 | $28.37M | $189.3M | $1.34 | Undisclosed Investors | |||||
| Ring Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $229.04M | Series D | 3/4/2026 | $50M | $300.05M | $2.06 | Undisclosed Investors | |||||
| ROME Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $199M | Series B | 9/24/2021 | $149M | $321.94M | $1.49 | Johnson & Johnson Innovation, Bristol Myers Squibb, Eurofarma Ventures, Luma Group, Mirae Asset Capital, Raycap, Sigmas Group, ARCH Ventures, GV, Section 32, Sanofi Ventures, Andreessen Horowitz, Mass General Brigham Ventures, Casdin Capital, Alexandria Venture Investments | |||||
| SynDevRx | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $52.6M | Series C | 9/30/2024 | $29.35M | $270.23M | $7.23 | Undisclosed Investors | |||||
| Taiga Biotechnologies | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $42.83M | Series C | 5/31/2019 | $27.2M | $442.88M | $6.80 | Undisclosed Investors | |||||
| TriSalus Life Sciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $198.81M | Series B-2 | 10/5/2022 | $15.32M | $375.88M | $0.35 | Undisclosed Investors | |||||
PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES
Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
Post-Money Valuation (valuation) represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions.
Sector and subsector descriptions focus primarily on the types of companies within the respective sectors and subsectors that are typically available through Forge Markets. Any sector or subsector as a whole may include companies that participate in business lines in other sectors or subsectors. Companies are classified into sectors and subsectors according to the problem(s) they seek to solve rather than the method by which the solution is delivered.